5.2 Ineligibility: 
A. Patients who fail to meet the above criteria. 
B. Patients who are hepatitis B surface antigen positive or HIV antibody 
positive , 
C. Patients who require steroids in any form- topical or systemic. 
D. Patients who have had therapy within 28 days 
E. Patients who are pregnant 
F. Patients with systemic infections or coagulation disorders 
G. Patients with an ECOG performance status >2. 
5.3 Patient Recruitment 
Patients will be recruited from those currently being evaluated at 
the University of Pittsburgh Medical Center. In addition information 
will be available through the Cancer Information Service 
(1 -800-4- CANCER) . All patients will have another physician not 
identifified with this protocol see them and participate in the decision 
of the patient to enter this experimental treatment. Patients will be 
given as much time as necessary to think about participation before 
signing the consent form but no less than one week. 
6.0 LOCATION 
All patients will be treated on the PCI inpatient or outpatient units of 
Montefiore University Hospital. All resected tissues, serum, and blood 
specimens will be processed by the IMDL/CT of the PCI located on the 10th 
floor of the BST at the University of Pittsburgh. Viral supernatant will be 
prepared in the HGTAL located in Biothechnology Center of University of 
Pittsburgh and approved for human use by the FDA. 
7.0 PATIENT EVALUATION 
7.1 Before Therapy: 
A. Complete physical exam including detailed measurement of all 
metastatic lesions. Recording of the cutaneous lesion(s) to be 
Injected will be performed including photography as necessary. 
B. Blood tests (85 ml) including: 
1. electrolytes, BUN, creatinine, AST, ALT, LDH, total bilirubin, 
direct bilirubin, alkaline phosphatase, glucose, calcium, 
magnesium, phosphorus, albumin, total protein, CEA. 
2. CBC with differential and platelet counts. 
3. PT, PTT. 
4. Pregnancy test for women who may conceive. 
Recombinant DNA Research, Volume 19 
[657] 
